Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

alcon couvreur - tobramycin - eye ointment - 0.3 %

Ουγκάντα - Αγγλικά - National Drug Authority

norvatis pharma ag- switzerland - tobramycin - ophthalmic drops - 0.3%w/v

Ναμίμπια - Αγγλικά - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - tobramycin - opthalmic ointment - tobramycin 3 mg/g

Ναμίμπια - Αγγλικά - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - tobramycin - opthalmic solution - tobramycin 3 mg/ml

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharma ag, switzerland - tobramycin - eye ointment - 0.3 %

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

stat rx usa llc - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - tobramycin 3 mg in 1 ml - tobradex® (tobramycin and dexamethasone ophthalmic suspension) is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common ba

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

alcon laboratories, inc. - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - tobramycin 3 mg in 1 ml - tobradex® st ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: stap

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - dexamethasone; tobramycin -

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

eyevance pharmaceuticals, llc - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - tobradex st ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: sta

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

anecortave acetate -